Skip to main content
. 2020 Nov 4;10(11):e038972. doi: 10.1136/bmjopen-2020-038972

Table 3.

One-year persistence with prophylactic migraine treatment

Total Antiserotonin agents Antidepressants Beta-blockers Antiepileptics Other anticonvulsants P value
N=599* (100%) N=123 (20.5%) N=110 (18.4%) N=51 (8.5%) N=132 (22.0%) N=183 (30.6%)
Persistent patients† 157 (26.2) 17 (13.8) 24 (21.8) 16 (31.4) 30 (22.7) 70 (38.3) <0.001
Non-peristent patients† 442 (73.8) 106 (86.2) 86 (78.2) 35 (68.6) 102 (77.3) 113 (61.7) <0.001
Full discontinuer‡ 205 (46.4) 42 (39.6) 43 (50.0) 12 (34.3) 46 (45.1) 62 (54.9)
Restarting‡ 137 (31.0) 19 (17.9) 24 (27.9) 18 (51.4) 36 (35.3) 40 (35.4)
Switch‡ 100 (22.6) 45 (42.5) 19 (22.1) 5 (14.3) 20 (19.6) 11 (9.7)
Days on treatment before stopping (discontinuation), median (IQR) 103.0 (89.0) 110.0 (79.0) 97.0 (120.0) 93.0 (78.5) 90.5 (71.0) 108.5 (87.0)
Days after treatment interruption before restarting, median (IQR) 46.0 (60.0) 39.0 (109.0) 59.5 (83.0) 65.0 (64.0) 26.5 (32.0) 50.0 (66.0)
Days on treatment before stopping (switching), median (IQR) 98.0 (57.5) 91.0 (42.0) 102.0 (44.0) 87.0 (57.0) 134.0 (76.0) 87.0 (60.0)

*Number of patients with prophylactic treatment is higher than that reported in table 2 as some patients who started treatment with both acute and prophylactic medications, later continued their treatment only with prophylactic medication.

†The percentage was calculated on the total of treated patients.

‡The percentage was calculated on the total of non-persistent patients.